Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Group 1 – Carriers of a changed TTR gene (or matched non-carriers) without heart failure:
- Men and women aged 30–80 who carry a disease-causing change in the TTR gene (or who are matched non-carriers), and who have no history of heart failure, meaning: no hospital stay for heart failure in the past 12 months, no recent blood test results showing elevated heart stress markers (BNP or NT-proBNP above certain levels), and no formal heart failure diagnosis from a doctor
- People who have signed an informed consent form agreeing to take part
Group 2 – People with symptomatic hereditary TTR heart disease (hATTR-CA):
- Men and women aged 30–80 who have been confirmed as having symptomatic hATTR-CA, shown by a history of heart failure — such as a hospital stay for heart failure in the past 12 months, elevated heart stress markers in recent blood tests, or a formal heart failure diagnosis from a treating doctor
- People who have an established or suspected diagnosis of hATTR-CA confirmed either by a tissue biopsy using special staining and analysis, or by a specific type of bone scan (technetium-99m pyrophosphate or bisphosphonate scan) combined with accepted laboratory results showing no abnormal protein
- People who have had, or are awaiting, genetic testing confirming a disease-causing change in the TTR gene
- People who have signed an informed consent form agreeing to take part
Who may not be able to join:
Group 1 – Carriers without heart failure:
- People with a personal or clinical history of heart failure
- People with other known causes of heart muscle disease
- People with a history of a different type of amyloidosis affecting the heart (light-chain cardiac amyloidosis)
- People who have had a previous heart attack (either type: NSTEMI or STEMI)
- People who have had a heart transplant
- People who weigh more than 250 pounds (approximately 113 kg)
- People whose kidneys are not working well enough (kidney function below a certain level, as measured by a blood test) (confirm with trial site)
- People who cannot safely have a cardiac MRI scan
Group 2 – People with symptomatic hATTR-CA:
- People with other known causes of heart muscle disease
- People with a history of light-chain cardiac amyloidosis
- People who have had a heart transplant
- People who have had a liver transplant
- People who have taken a TTR stabiliser medication (tafamidis or acoramidis) within the past 14 days, or who have ever taken a TTR silencer medication (inotersen, patisiran, or eplontersen)
- People whose kidneys are not working well enough (kidney function below a certain level, as measured by a blood test) (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Justin L Grodin, MD MPH, UT Southwestern
Phone: 214-645-8040
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
(Aim 1) Evidence of amyloid infiltration as measured by ECV; (Sub-aim 1) Δ stroke volume index (ΔSVi)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.